A
Angel Garcia-Diaz
Researcher at University of California, Los Angeles
Publications - 9
Citations - 2496
Angel Garcia-Diaz is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Interferon & Blockade. The author has an hindex of 8, co-authored 9 publications receiving 1657 citations. Previous affiliations of Angel Garcia-Diaz include University of California.
Papers
More filters
Journal ArticleDOI
Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Angel Garcia-Diaz,Daniel Sanghoon Shin,Blanca Homet Moreno,Justin Saco,Helena Escuin-Ordinas,Gabriel Abril Rodriguez,Jesse M. Zaretsky,Lu Sun,Willy Hugo,Xiaoyan Wang,Giulia Parisi,Cristina Puig Saus,Davis Y. Torrejon,Thomas G. Graeber,Begonya Comin-Anduix,Siwen Hu-Lieskovan,Robert Damoiseaux,Roger S. Lo,Antoni Ribas +18 more
TL;DR: Analysis of biopsy specimens from patients with melanoma confirmed interferon signature enrichment and upregulation of gene targets for STAT1/STAT2/STAT3 and IRF1 in anti-PD-1-responding tumors.
Journal ArticleDOI
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin,Jesse M. Zaretsky,Helena Escuin-Ordinas,Angel Garcia-Diaz,Siwen Hu-Lieskovan,Anusha Kalbasi,Catherine S. Grasso,Willy Hugo,Salemiz Sandoval,Davis Y. Torrejon,Nicolaos Palaskas,Gabriel Abril Rodriguez,Giulia Parisi,Ariel M. Azhdam,Bartosz Chmielowski,Grace Cherry,Elizabeth Seja,Beata Berent-Maoz,I. Peter Shintaku,Dung Thi Le,Drew M. Pardoll,Luis A. Diaz,Paul C. Tumeh,Thomas G. Graeber,Roger S. Lo,Begoña Comin-Anduix,Antoni Ribas +26 more
TL;DR: It is proposed that JAK1/2 loss-of-function mutations are a genetic mechanism of lack of reactive PD-L1 expression and response to interferon gamma, leading to primary resistance to PD-1 blockade therapy.
Journal ArticleDOI
Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance.
Yapeng Su,Wei Wei,Wei Wei,Lidia Robert,Min Xue,Jennifer Tsoi,Angel Garcia-Diaz,Blanca Homet Moreno,Blanca Homet Moreno,Jungwoo Kim,Rachel Ng,Jihoon W. Lee,Richard C. Koya,Begonya Comin-Anduix,Thomas G. Graeber,Antoni Ribas,James R. Heath,James R. Heath +17 more
TL;DR: Biophysical insights are provided into how BRAF mutant melanoma cells adapt to the stress of MAPK inhibition via a series of reversible phenotypic transitions toward drug-tolerant or drug-resistant cell states enriched for neural-crest factors and mesenchymal signatures.
Journal ArticleDOI
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T Cells.
Blanca Homet Moreno,Jesse M. Zaretsky,Angel Garcia-Diaz,Jennifer Tsoi,Giulia Parisi,Lidia Robert,Katrina Meeth,Abibatou Ndoye,Marcus Bosenberg,Ashani T. Weeraratna,Thomas G. Graeber,Begoña Comin-Anduix,Siwen Hu-Lieskovan,Antoni Ribas +13 more
TL;DR: Response to PD-1 blockade therapy in tumor models requires CD4 and CD8 T cells and costimulation that is mediated by dendritic cells and macrophages, and exhibited a more inflammatory profile by RNA sequencing analysis.
Journal ArticleDOI
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
Davis Y. Torrejon,Gabriel Abril-Rodriguez,Ameya Champhekar,Jennifer Tsoi,Katie M. Campbell,Anusha Kalbasi,Giulia Parisi,Jesse M. Zaretsky,Angel Garcia-Diaz,Cristina Puig-Saus,Gardenia Cheung-Lau,Thomas Wohlwender,Paige Krystofinski,Agustin Vega-Crespo,Christopher M. Lee,Pau Mascaro,Catherine S. Grasso,Beata Berent-Maoz,Begoña Comin-Anduix,Siwen Hu-Lieskovan,Antoni Ribas +20 more
TL;DR: Mechanism-based strategies to overcome resistance to programmed cell death-1 (PD-1) blockade therapy are urgently needed and mechanistically-designed combination therapies can overcome genetic resistance to PD-1 blockade therapy.